Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

An Investigation of The Relationship Between Muscle Mass, Physiological Parameters, and Blood Gas Levels in Adult Patients Hospitalized in The Intensive Care Unit

NCT07866625 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-12-10
Last updated
2026-10-08

Condition(s) studied

Intensive Care (ICU)

Study summary

This study was designed to investigate the relationship between muscle mass and physiological parameters and blood gas values in adult patients admitted to the intensive care unit. While muscle mass will be determined using anthropometric measurements, SpO₂, pulse rate, blood pressure, diuresis, and arterial blood gas values will be evaluated. The primary hypothesis of the study is that there is a significant relationship between muscle mass and, in particular, oxygenation and other physiological and blood gas parameters.

Eligibility

Sex
ALL
Min age
18 Hours
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Inclusion Criteria: Age: Adult patients aged 18 years and older Clinical unit: Patients admitted to palliative care, pulmonary intensive care, or cardiovascular intensive care units Length of stay: Patients expected to remain in the intensive care unit for at least 48 hours Physical eligibility: Patients with no conditions preventing the measurement of muscle mass Clinical stability: Patients without severe hemodynamic instability or active bleeding at the time of measurement Ethical compliance: Individuals who have volunteered to participate in the study and whose informed consent has been obtained from them or their legal representative Exclusion Criteria: * Exclusion Criteria: * Patients with a history of previously diagnosed neuromuscular disorders (myasthenia gravis, Guillain-Barré syndrome, chronic polyneuropathies) * Patients with severe renal or hepatic insufficiency that could directly affect muscle mass * Presence of severe edema: Patients with a pitting edema score of 3+ or 4+ on the pitting edema test, or individuals with documented widespread edema in nursing or medical records * Patients with an amputation, hematoma, or open wound on the extremity to be measured * Pregnant patients * Patients whose intensive care stay lasted less than 48 hours or for whom the measurement could not be completed due to discharge or death

Primary outcome measure(s)

  • muscle mass — 10.12.2026

Trial sites (1)

FacilityCityRegionStatus
Erzurum City Hospital, Erzurum Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07866625 on ClinicalTrials.gov ↗ ← All trials in Turkey